Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Neuren Pharmaceuticals secures third FDA Fast Track for NNZ-2591 as shares rise 4.21% Find out how Neuren Pharmaceuticals is expanding FDA Fast Track coverage for NNZ‑2591 across rare disorders like PMS, AS, and Pitt Hopkins. byVenkateshOctober 20, 2025